IFNG and hepatocellular carcinoma: However, in another preclinical investigation, the researchers discovered that in the presence of IFN-γ, regorafenib could upregulate the expression of MCH-I on HCC cells by acting on the IFN-γ/STAT1 signaling pathway (133).